Comparison of side effects and tolerability between intravesical bacillus calmette-guerin, reduced-dose BCG, and gemcitabine for non-muscle invasive bladder cancer

UrologyKuperus JM, Busman RD, Kuipers SK, et al. | July 02, 2021

Advertisement

This research sought to correlate patient-reported side effects and tolerability of full-dose Bacillus Calmette-Guérin (BCG), reduced-dose BCG, and gemcitabine one week after administration. Between July 2019 and November 2020, all individuals receiving intravesical therapy (IVT) for non-muscle invasive bladder cancer (NMIBC) at our institution were surveyed before repeat instillation. A total of 592 surveys were completed, symptoms of any kind were reported on 463 surveys (78%) with the most common symptoms including bladder symptoms (59%), fatigue (52%), body aches (26%), and hematuria (18%). Using this novel survey, there were significant differences in the side effects and tolerability of full-dose BCG, reduced-dose BCG, and gemcitabine, and these differences are of value for informing IVT selection. For NMIBC, assessment of IVTs other than gemcitabine and BCG will further inform selection of therapies.

Read the full article on Urology

Advertisement